NCT Number |
Title |
Conditions |
Interventions |
Sponsor
Collaborators |
Phases |
NCT03339921 |
Botulinum for Chronic Exertional Compartment Syndrome |
Chronic Exertional Compartment Syndrome |
Drug: Botulinum toxin injections for chronic compartment syndrome|Procedure: surgical fasciotomy for chronic compartment syndrome |
375th Medical Group,
Scott Air Force Base |
Phase 2
Phase 3 |
NCT03338959 |
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma |
Soft Tissue Sarcoma |
Biological: Pembrolizumab|Radiation: Radiation Therapy |
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI) |
Phase 1
Phase 2 |
NCT03333590 |
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy |
Duchenne Muscular Dystrophy |
Biological: rAAVrh74.MCK.GALGT2 |
Kevin Flanigan
Nationwide Children's Hospital |
Phase 1
Phase 2 |
NCT03340558 |
Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer |
Metastatic Colorectal Cancer |
Biological: Atezolizumab|Drug: Cobimetinib |
Niharika Mettu
Genentech/Roche
Duke University |
Phase 2 |
NCT03339713 |
A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health |
Healthy |
Biological: Ad26.RSV.preF|Biological: Fluarix|Biological: Placebo |
Janssen Vaccines & Prevention B.V. |
Phase 2 |
NCT03338972 |
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|TNFRSF17 Positive |
Biological: BCMA-specific CAR-expressing T Lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis |
Fred Hutchinson Cancer Research Center
Juno Therapeutics, Inc.
National Cancer Institute (NCI) |
Phase 1 |
NCT03337542 |
AR101 Real-World Open-Label Extension Study |
Peanut Allergy |
Biological: AR101 |
Aimmune Therapeutics, Inc. |
Phase 3 |
NCT03333616 |
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
Genitourinary Cancer|Adrenocortical Carcinoma|Non-urothelial Bladder|Non-urothelial Upper Tract|Penile Cancer|Non-adenocarcinoma Prostate Cancer|Refractory Germ-cell |
Drug: Ipilimumab|Drug: Nivolumab |
Dana-Farber Cancer Institute
Bristol-Myers Squibb |
Phase 2 |
NCT03336333 |
A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL |
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma |
Drug: BGB-3111|Drug: Bendamustine|Drug: Rituximab |
BeiGene |
Phase 3 |
NCT03336216 |
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer |
Advanced Pancreatic Cancer |
Biological: Cabiralizumab|Drug: Nab-paclitaxel|Drug: Onivyde|Biological: Nivolumab|Drug: Fluorouracil|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Leucovorin |
Bristol-Myers Squibb |
Phase 2 |
NCT03337698 |
A Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
Drug: Atezolizumab|Drug: Cobimetinib|Drug: RO6958688|Drug: Docetaxel|Drug: BL-8040|Drug: Tazemetostat|Drug: CPI-444|Drug: Pemetrexed|Drug: Carboplatin|Drug: Gemcitabine |
Hoffmann-La Roche |
Phase 1
Phase 2 |
NCT03338790 |
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer |
Prostate Cancer |
Biological: Nivolumab|Drug: Docetaxel|Drug: Enzalutamide|Drug: Rucaparib|Drug: Prednisone |
Bristol-Myers Squibb
Clovis Oncology
Astellas Pharma Inc |
Phase 2 |
NCT03337477 |
A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ¡Ã6.0 . |
Hyperkalemia |
Drug: Placebo|Drug: Sodium Zirconium Cyclosilicate(ZS)|Drug: Insulin|Drug: Glucose |
AstraZeneca |
Phase 2 |
NCT03334617 |
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy. |
Non-Small Cell Lung Cancer |
Drug: Durvalumab|Drug: AZD9150|Drug: AZD6738|Drug: Vistusertib|Drug: Olaparib |
AstraZeneca |
Phase 2 |